Business & Finance
MiMedx's Q2 revenue of USD76.4m exceeds guidance range
14 July 2017 -

Biopharmaceutical company MiMedx Group Inc (NASDAQ:MDXG) announced on Thursday that its revenue was USD76.4m for the second quarter of 2017.

This marks a growth of 33% over the revenue of USD57.3m in the Q2 2016.

The company added that its second quarter 2017 revenue of USD76.4m exceeds the guidance range of USD73.5m to USD75.0m.

Revenues of USD149m were generated for the six months ended 30 June 2017, up USD38.3m (35%) from revenue of USD110.7m for the six months ended 30 June 2016.

In addition, the company plans to release its full results for the second quarter ended 30 June 2017, before the opening of the market on 27 July 2017 as well as provide revenue guidance for the third quarter of 2017 in that quarterly earnings release.

Login
Username:

Password: